Amphastar Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $17.3M | $24.3M | $19.8M | $29.5M | $7.8M | $5.0M | $-6.3M | $3.9M |
| Depreciation & Amortization | $3.0M | $2.7M | $2.6M | $2.5M | $2.6M | $2.5M | $2.5M | $2.5M |
| Depreciation | $5.8M | $5.6M | $5.4M | $5.4M | $5.8M | $5.7M | $5.5M | $5.4M |
| Amortization | $152.0K | $352.0K | $141.0K | $377.0K | $277.0K | $276.0K | $265.0K | $262.0K |
| Stock-Based Compensation | $4.2M | $5.0M | $3.9M | $3.9M | $6.1M | $4.8M | $4.3M | $4.4M |
| Net Cash from Operating Activities | $2.8M | $50.8M | $40.4M | $2.6M | $32.2M | $22.8M | $16.9M | $8.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.0M | $6.1M | $6.9M | $7.2M | $5.7M | $7.6M | $9.3M | $5.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-8.2M | $-9.1M | $-12.0M | $-3.8M | $-4.3M | $-8.7M | $-12.2M | $-5.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $6.1M | $1.2M | $13.4M | $6.1M | $5.6M | $3.8M | $3.4M | $4.3M |
| Net Cash from Financing Activities | $-994.0K | $4.6M | $-8.7M | $-16.5M | $-5.2M | $-6.6M | $-227.0K | $-3.0M |
| Net Change in Cash | $-6.5M | $46.3M | $19.7M | $-17.7M | $22.8M | $7.3M | $4.7M | $522.0K |
| Free Cash Flow | $-3.1M | $44.6M | $33.6M | $-4.7M | $26.4M | $15.2M | $7.6M | $3.2M |